(175-17) A randomized phase II study comparing selumetinib to placebo for enhancing the clinical efficacy of radioactive iodine (RAI) for recurrent/metastatic thyroid cancers that retain RAI uptake (Phase 2 clinical trial, appropriate for patients with thyroid cancer.)
Principal Investigator: Michael J. Demeure, M.D., F.A.C.S., F.A.C.E.
Sub-Principal Investigator: George B. Semeniuk, M.D.